Intestinal lymphatic transport for drug delivery

Advanced Drug Delivery Reviews

Volumn 63, Issue 10-11, 2011, Pages 923-942

  Yáñez, Jaime A ^a   Wang, Stephen W J ^a   Knemeyer, Ian W ^a   Wirth, Mark A ^a   Alton, Kevin B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Absorption; Chylomicron; Delivery; Drugs; Formulation; Intestine; Lipid; Lymph; Oral; Transport

Indexed keywords

CHYLOMICRON; DELIVERY; DRUGS; FORMULATION; INTESTINE; LYMPH; ORAL; TRANSPORT;

LIPIDS; METABOLISM; PHYSIOLOGICAL MODELS; PHYSIOLOGY;

DRUG DELIVERY;

ABC TRANSPORTER; AMIODARONE; CARBAMAZEPINE; CHYLOMICRON; CYCLOSPORIN A; CYTOCHROME P450; DANAZOL; DIACYLGLYCEROL DERIVATIVE; DICLOFENAC; EXCIPIENT; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; HALOFANTRINE; IBUPROFEN; KETOCONAZOLE; LIPID; LIPOPROTEIN; MEFENAMIC ACID; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN; NAPROXEN; PARACETAMOL; PHOSPHOLIPID; RITONAVIR; SAQUINAVIR; TAMOXIFEN; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

COMPUTER MODEL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; DRUG UPTAKE; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CELL; INTESTINE LYMPH; MICROEMULSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH HEMORRHAGE; STOMACH PERFORATION; STOMACH ULCER;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; CHYLOMICRONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPIDS; LYMPHATIC SYSTEM; PRODRUGS;

EID: 80052168589     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.05.019     Document Type: Review

References (287)

1. Charman W.N., Stella V.J. Estimating the maximum potential for intestinal lymphatic transport of lipophillic drug molecules. Int. J. Pharm. 1986, 34:175-178.
2. Trevaskis N.L., Charman W.N., Porter C.J. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 2008, 60:702-716.
3. Nordskog B.K., Phan C.T., Nutting D.F., Tso P. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv. Drug Deliv. Rev. 2001, 50:21-44.
4. Cense H.A., van Eijck C.H., Tilanus H.W. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract. Res. Clin. Gastroenterol. 2006, 20:893-906.
5. Arya M., Bott S.R., Shergill I.S., Ahmed H.U., Williamson M., Patel H.R. The metastatic cascade in prostate cancer. Surg. Oncol. 2006, 15:117-128.
6. Muranishi S. Lymphatic delivery of drugs and its application to cancer chemotherapy (author's transl). Yakugaku Zasshi 1980, 100:687-698.
7. Garzon-Aburbeh A., Poupaert J.H., Claesen M., Dumont P., Atassi G. 1,3-dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent. J. Med. Chem. 1983, 26:1200-1203.
8. Pantaleo G., Graziosi C., Demarest J.F., Cohen O.J., Vaccarezza M., Gantt K., Muro-Cacho C., Fauci A.S. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol. Rev. 1994, 140:105-130.
9. Pantaleo G., Graziosi C., Fauci A.S. The role of lymphoid organs in the immunopathogenesis of HIV infection. AIDS 1993, 7(Suppl. 1):S19-S23.
10. Umeda M., Marusawa H., Seno H., Katsurada A., Nabeshima M., Egawa H., Uemoto S., Inomata Y., Tanaka K., Chiba T. Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers. J. Hepatol. 2005, 42:806-812.
11. von Messling V., Svitek N., Cattaneo R. Receptor (SLAM [CD150]) recognition and the V protein sustain swift lymphocyte-based invasion of mucosal tissue and lymphatic organs by a morbillivirus. J. Virol. 2006, 80:6084-6092.
12. Lan N.T., Yamaguchi R., Inomata A., Furuya Y., Uchida K., Sugano S., Tateyama S. Comparative analyses of canine distemper viral isolates from clinical cases of canine distemper in vaccinated dogs. Vet. Microbiol. 2006, 115:32-42.
13. Spiegel M., Schneider K., Weber F., Weidmann M., Hufert F.T. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. J. Gen. Virol. 2006, 87:1953-1960.
14. Kessel A., Toubi E. Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism. Curr. Med. Chem. 2007, 14:547-554.
15. Lalanne M., Paci A., Andrieux K., Dereuddre-Bosquet N., Clayette P., Deroussent A., Re M., Vassal G., Couvreur P., Desmaele D. Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg. Med. Chem. Lett. 2007, 17:2237-2240.
16. Tso P. Intestinal lymphatic transport of lipids. Adv. Drug Deliv. Rev. 2001, 50:21-44.
17. Phan C.T., Tso P. Intestinal lipid absorption and transport. Front. Biosci. 2001, 6:D299-D319.
18. Tso P. Intestinal lipid absorption. Physiology of the Gastrointestinal Tract 1994, 1867-1907. Raven Press, New York. L.R. Johnson (Ed.).
19. Thomson A.B., Keelan M., Garg M.L., Clandinin M.T. Intestinal aspects of lipid absorption: in review. Can. J. Physiol. Pharmacol. 1989, 67:179-191.
20. Davidson N.O. Cellular and molecular mechanisms of small intestinal lipid transport. Physiology of the Gastrointestinal Tract 1994, 1909-1934. Raven Press, New York. L.R. Johnson (Ed.).
21. Carey M.C., Small D.M., Bliss C.M. Lipid digestion and absorption. Annu. Rev. Physiol. 1983, 45:651-677.
22. Nutting D.F., Kumar N.S., St Hilaire R.J., Mansbach C.M. Nutrient absorption. Curr. Opin. Clin. Nutr. Metab. Care 1999, 2:413-419.
23. Abrams C.K., Hamosh M., Lee T.C., Ansher A.F., Collen M.J., Lewis J.H., Benjamin S.B., Hamosh P. Gastric lipase: localization in the human stomach. Gastroenterology 1988, 95:1460-1464.
24. Hamosh M., Scanlon J.W., Ganot D., Likel M., Scanlon K.B., Hamosh P. Fat digestion in the newborn. Characterization of lipase in gastric aspirates of premature and term infants. J. Clin. Invest. 1981, 67:838-846.
25. Cohen M., Morgan R.G., Hofmann A.F. Lipolytic activity of human gastric and duodenal juice against medium and long chain triglycerides. Gastroenterology 1971, 60:1-15.
26. Mattson F.H., Volpenhein R.A. Hydrolysis of primary and secondary esters of glycerol by pancreatic juice. J. Lipid Res. 1968, 9:79-84.
27. Shiau Y.F. Mechanism of intestinal fat absorption. Am. J. Physiol. 1981, 240:G1-G9.
28. Mattson F.H., Beck L.W. The specificity of pancreatic lipase for the primary hydroxyl groups of glycerides. J. Biol. Chem. 1956, 219:735-740.
29. Mattson F.H., Volpenhein R.A. The digestion and absorption of triglycerides. J. Biol. Chem. 1964, 239:2772-2777.
30. Hofmann A.F., Borgstrom B. Hydrolysis of long-chain monoglycerides in micellar solution by pancreatic lipase. Biochim. Biophys. Acta 1963, 70:317-331.
31. Borgstrom B., Dahlqvist A., Lundh G., Sjovall J. Studies of intestinal digestion and absorption in the human. J. Clin. Invest. 1957, 36:1521-1536.
32. van den Bosch H., Postema N.M., de Haas G.H., van Deenen L.L. On the positional specificity of phospholipase A from pancreas. Biochim. Biophys. Acta 1965, 98:657-659.
33. McIntyre N. Cholesterol absoprtion. Lipid Absorption: Biochemical and Clinical Aspects 1976, 73-84. MTP Press Ltd., London. K. Rommel, H. Goebell, R. Bhomer (Eds.).
34. Erlanson C. Purification, properties, and substrate specificity of a carboxylesterase in pancreatic juice. Scand. J. Gastroenterol. 1975, 10:401-408.
35. Staggers J.E., Hernell O., Stafford R.J., Carey M.C. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry 1990, 29:2028-2040.
36. Hernell O., Staggers J.E., Carey M.C. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry 1990, 29:2041-2056.
37. Shiau Y.F. Mechanism of intestinal fatty acid uptake in the rat: the role of an acidic microclimate. J. Physiol. 1990, 421:463-474.
38. Hoffman N.E. The relationship between uptake in vitro of oleic acid and micellar solubilization. Biochim. Biophys. Acta 1970, 196:193-203.
39. Simmonds W.J. The role of micellar solubilization in lipid absorption. Aust. J. Exp. Biol. Med. Sci. 1972, 50:403-421.
40. Chijiiwa K., Linscheer W.G. Effect of intraluminal pH on cholesterol and oleic acid absorption from micellar solutions in the rat. Am. J. Physiol. 1984, 246:G492-G499.
41. Shiau Y.F., Kelemen R.J., Reed M.A. Acidic mucin layer facilitates micelle dissociation and fatty acid diffusion. Am. J. Physiol. 1990, 259:G671-G675.
42. Chijiiwa K., Linscheer W.G. Mechanism of pH effect on oleic acid and cholesterol absorption in the rat. Am. J. Physiol. 1987, 252:G506-G510.
43. Thomson A.B., Schoeller C., Keelan M., Smith L., Clandinin M.T. Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can. J. Physiol. Pharmacol. 1993, 71:531-555.
44. Schoeller C., Keelan M., Mulvey G., Stremmel W., Thomson A.B. Role of a brush border membrane fatty acid binding protein in oleic acid uptake into rat and rabbit jejunal brush border membrane. Clin. Invest. Med. 1995, 18:380-388.
45. Schoeller C., Keelan M., Mulvey G., Stremmel W., Thomson A.B. Oleic acid uptake into rat and rabbit jejunal brush border membrane. Biochim. Biophys. Acta 1995, 1236:51-64.
46. Stremmel W., Lotz G., Strohmeyer G., Berk P.D. Identification, isolation, and partial characterization of a fatty acid binding protein from rat jejunal microvillous membranes. J. Clin. Invest. 1985, 75:1068-1076.
47. Stremmel W. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein. J. Clin. Invest. 1988, 82:2001-2010.
48. Poirier H., Degrace P., Niot I., Bernard A., Besnard P. Localization and regulation of the putative membrane fatty-acid transporter (FAT) in the small intestine. Comparison with fatty acid-binding proteins (FABP). Eur. J. Biochem. 1996, 238:368-373.
49. Bloom B., Chaikoff I.L., Reinhardt Intestinal lymph as pathway for transport of absorbed fatty acids of different chain lengths. Am. J. Physiol. 1951, 166:451-455.
50. Chaikoff I.L., Bloom B., Stevens B.P., Reinhardt W.O., Dauben W.G. Pentadecanoic acid-5-C14; its absorption and lymphatic transport. J. Biol. Chem. 1951, 190:431-435.
51. Bloom B., Chaikoff I.L., Reinhardt W.O., Dauben W.G. Participation of phospholipides in lymphatic transport of absorbed fatty acids. J. Biol. Chem. 1951, 189:261-267.
52. Kiyasu J.Y., Bloom B., Chaikoff I.L. The portal transport of absorbed fatty acids. J. Biol. Chem. 1952, 199:415-419.
53. Storch J., Thumser A.E. The fatty acid transport function of fatty acid-binding proteins. Biochim. Biophys. Acta 2000, 1486:28-44.
54. Luxon B.A., Milliano M.T. Cytoplasmic transport of fatty acids in rat enterocytes: role of binding to fatty acid-binding protein. Am. J. Physiol. 1999, 277:G361-G366.
55. Ockner R.K., Kaikaus R.M., Bass N.M. Fatty acid binding proteins: recent concepts of regulation and function. Prog. Clin. Biol. Res. 1992, 375:189-204.
56. Thumser A.E., Storch J. Liver and intestinal fatty acid-binding proteins obtain fatty acids from phospholipid membranes by different mechanisms. J. Lipid Res. 2000, 41:647-656.
57. Alpers D.H., Bass N.M., Engle M.J., DeSchryver-Kecskemeti K. Intestinal fatty acid binding protein may favor differential apical fatty acid binding in the intestine. Biochim. Biophys. Acta 2000, 1483:352-362.
58. Levin M.S., Talkad V.D., Gordon J.I., Stenson W.F. Trafficking of exogenous fatty acids within Caco-2 cells. J. Lipid Res. 1992, 33:9-19.
59. Porter C.J., Charman W.N. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 2001, 50:61-80.
60. Senior J.R., Isselbacher K.J. Direct esterification of monoglycerides with palmityl coenzyme A by intestinal epithelial subcellular fractions. J. Biol. Chem. 1962, 237:1454-1459.
61. Levy E., Mehran M., Seidman E. Caco-2 cells as a model for intestinal lipoprotein synthesis and secretion. FASEB J. 1995, 9:626-635.
62. Ockner R.K., Hughes F.B., Isselbacher K.J. Very low density lipoproteins in intestinal lymph: origin, composition, and role in lipid transport in the fasting state. J. Clin. Invest. 1969, 48:2079-2088.
63. Hussain M.M. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000, 148:1-15.
64. Tso P., Lindstrom M.B., Borgstrom B. Factors regulating the formation of chylomicrons and very-low-density lipoproteins by the rat small intestine. Biochim. Biophys. Acta 1987, 922:304-313.
65. Ockner R.K., Hughes F.B., Isselbacher K.J. Very low density lipoproteins in intestinal lymph: role in triglyceride and cholesterol transport during fat absorption. J. Clin. Invest. 1969, 48:2367-2373.
66. van Greevenbroek M.M., de Bruin T.W. Chylomicron synthesis by intestinal cells in vitro and in vivo. Atherosclerosis 1998, 141(Suppl. 1):S9-S16.
67. Gordon D.A., Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim. Biophys. Acta 2000, 1486:72-83.
68. Tso P., Balint J.A., Rodgers J.B. Effect of hydrophobic surfactant (Pluronic L-81) on lymphatic lipid transport in the rat. Am. J. Physiol. 1980, 239:G348-G353.
69. Tso P., Drake D.S., Black D.D., Sabesin S.M. Evidence for separate pathways of chylomicron and very low-density lipoprotein assembly and transport by rat small intestine. Am. J. Physiol. 1984, 247:G599-G610.
70. Tso P., Balint J.A., Bishop M.B., Rodgers J.B. Acute inhibition of intestinal lipid transport by Pluronic L-81 in the rat. Am. J. Physiol. 1981, 241:G487-G497.
71. Tso P., Balint J.A. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am. J. Physiol. 1986, 250:G715-G726.
72. Mahley R.W., Bennett B.D., Morre D.J., Gray M.E., Thistlethwaite W., LeQuire V.S. Lipoproteins associated with the Golgi apparatus isolated from epithelial cells of rat small intestine. Lab. Investig. 1971, 25:435-444.
73. Vahouny G.V., Blendermann E.M., Gallo L.L., Treadwell C.R. Differential transport of cholesterol and oleic acid in lymph lipoproteins: sex differences in puromycin sensitivity. J. Lipid Res. 1980, 21:415-424.
74. Tso P., Kendrick H., Balint J.A., Simmonds W.J. Role of biliary phosphatidylcholine in the absorption and transport of dietary triolein in the rat. Gastroenterology 1981, 80:60-65.
75. Nutting D., Hall J., Barrowman J.A., Tso P. Further studies on the mechanism of inhibition of intestinal chylomicron transport by Pluronic L-81. Biochim. Biophys. Acta 1989, 1004:357-362.
76. Luchoomun J., Hussain M.M. Assembly and secretion of chylomicrons by differentiated Caco-2 cells. Nascent triglycerides and preformed phospholipids are preferentially used for lipoprotein assembly. J. Biol. Chem. 1999, 274:19565-19572.
77. Graham D.L., Knott T.J., Jones T.C., Pease R.J., Pullinger C.R., Scott J. Carboxyl-terminal truncation of apolipoprotein B results in gradual loss of the ability to form buoyant lipoproteins in cultured human and rat liver cell lines. Biochemistry 1991, 30:5616-5621.
78. McLeod R.S., Zhao Y., Selby S.L., Westerlund J., Yao Z. Carboxyl-terminal truncation impairs lipid recruitment by apolipoprotein B100 but does not affect secretion of the truncated apolipoprotein B-containing lipoproteins. J. Biol. Chem. 1994, 269:2852-2862.
79. Young S.G., Cham C.M., Pitas R.E., Burri B.J., Connolly A., Flynn L., Pappu A.S., Wong J.S., Hamilton R.L., Farese R.V. A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine. J. Clin. Invest. 1995, 96:2932-2946.
80. Hamilton R.L., Wong J.S., Cham C.M., Nielsen L.B., Young S.G. Chylomicron-sized lipid particles are formed in the setting of apolipoprotein B deficiency. J. Lipid Res. 1998, 39:1543-1557.
81. Trevaskis N.L., Porter C.J., Charman W.N. Bile increases intestinal lymphatic drug transport in the fasted rat. Pharm. Res. 2005, 22:1863-1870.
82. Baxter J. Origin and characteristics of endogenous lipid in thoracic duct lymph in rat. J. Lipid Res. 1966, 7:158-166.
83. Byers S.O., Friedman M. Site of origin of plasma triglyceride. Am. J. Physiol. 1960, 198:629-631.
84. Risser T.R., Reaven G.M., Reaven E.P. Intestinal contribution to secretion of very low density lipoproteins into plasma. Am. J. Physiol. 1978, 234:E277-E281.
85. Shiau Y.F., Popper D.A., Reed M., Umstetter C., Capuzzi D., Levine G.M. Intestinal triglycerides are derived from both endogenous and exogenous sources. Am. J. Physiol. 1985, 248:G164-G169.
86. Mansbach C.M., Dowell R.F. Uptake and metabolism of circulating fatty acids by rat intestine. Am. J. Physiol. 1992, 263:G927-G933.
87. Mansbach C.M., Dowell R.F. Role of the intestine in chylomicron remnant clearance. Am. J. Physiol. 1995, 269:G144-G152.
88. Mansbach C.M., Arnold A., Cox M.A. Factors influencing triacylglycerol delivery into mesenteric lymph. Am. J. Physiol. 1985, 249:G642-G648.
89. Tso P., Balint J.A., Simmonds W.J. Role of biliary lecithin in lymphatic transport of fat. Gastroenterology 1977, 73:1362-1367.
90. Hofmann A.F., Borgstrom B. Physico-chemical state of lipids in intestinal content during their digestion and absorption. Fed. Proc. 1962, 21:43-50.
91. Shackleford D.M., Faassen W.A., Houwing N., Lass H., Edwards G.A., Porter C.J., Charman W.N. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J. Pharmacol. Exp. Ther. 2003, 306:925-933.
92. Frey H., Aakvaag A., Saanum D., Falch J. Bioavailability of oral testosterone in males. Eur. J. Clin. Pharmacol. 1979, 16:345-349.
93. Bagchus W.M., Hust R., Maris F., Schnabel P.G., Houwing N.S. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 2003, 23:319-325.
94. Khoo S.M., Edwards G.A., Porter C.J., Charman W.N. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J. Pharm. Sci. 2001, 90:1599-1607.
95. Khoo S.M., Prankerd R.J., Edwards G.A., Porter C.J., Charman W.N. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. J. Pharm. Sci. 2002, 91:647-659.
96. Ockner R.K., Manning J.A. Fatty acid-binding protein in small intestine. Identification, isolation, and evidence for its role in cellular fatty acid transport. J. Clin. Invest. 1974, 54:326-338.
97. Zilversmit D.B. The composition and structure of lymph chylomicrons in dog, rat, and man. J. Clin. Invest. 1965, 44:1610-1622.
98. Lindgren F.T., Jensen L.C., Hatch F.T. The isolation and quantitative analysis of serum lipoproteins. Blood lipids and Lipoproteins: Quantitation, Composition and Metabolism 1972, 181-274. Wiley, New York. G.J. Nelson (Ed.).
99. Carey M.C., Small D.M. The characteristics of mixed micellar solutions with particular reference to bile. Am. J. Med. 1970, 49:590-608.
100. Edge S.B., Hoeg J.M., Schneider P.D., Brewer H.B. Apolipoprotein B synthesis in humans: liver synthesizes only apolipoprotein B-100. Metabolism 1985, 34:726-730.
101. Glickman R.M., Rogers M., Glickman J.N. Apolipoprotein B synthesis by human liver and intestine in vitro. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:5296-5300.
102. Glickman R.M., Glickman J.N., Magun A., Brin M. Apolipoprotein synthesis in normal and abetalipoproteinemic intestinal mucosa. Gastroenterology 1991, 101:749-755.
103. Berriot-Varoqueaux N., Dannoura A.H., Moreau A., Verthier N., Sassolas A., Cadiot G., Lachaux A., Munck A., Schmitz J., Aggerbeck L.P., Samson-Bouma M.E. Apolipoprotein B48 glycosylation in abetalipoproteinemia and Anderson's disease. Gastroenterology 2001, 121:1101-1108.
104. Levy R.I., Fredrickson D.S., Laster L. The lipoproteins and lipid transport in abetalipoproteinemia. J. Clin. Invest. 1966, 45:531-541.
105. Ohashi K., Ishibashi S., Osuga J., Tozawa R., Harada K., Yahagi N., Shionoiri F., Iizuka Y., Tamura Y., Nagai R., Illingworth D.R., Gotoda T., Yamada N. Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. J. Lipid Res. 2000, 41:1199-1204.
106. Berriot-Varoqueaux N., Aggerbeck L.P., Samson-Bouma M., Wetterau J.R. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu. Rev. Nutr. 2000, 20:663-697.
107. Hooper A.J., van Bockxmeer F.M., Burnett J.R. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit. Rev. Clin. Lab. Sci. 2005, 42:515-545.
108. Anderson C.M., Townley R.R., Freemanm, Johansen P. Unusual causes of steatorrhoea in infancy and childhood. Med. J. Aust. 1961, 48(2):617-622.
109. Roy C.C., Levy E., Green P.H., Sniderman A., Letarte J., Buts J.P., Orquin J., Brochu P., Weber A.M., Morin C.L., et al. Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B, chylomicron retention disease. Gastroenterology 1987, 92:390-399.
110. Dannoura A.H., Berriot-Varoqueaux N., Amati P., Abadie V., Verthier N., Schmitz J., Wetterau J.R., Samson-Bouma M.E., Aggerbeck L.P. Anderson's disease: exclusion of apolipoprotein and intracellular lipid transport genes. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2494-2508.
111. Silvain M., Bligny D., Aparicio T., Laforet P., Grodet A., Peretti N., Menard D., Djouadi F., Jardel C., Begue J.M., Walker F., Schmitz J., Lachaux A., Aggerbeck L.P., Samson-Bouma M.E. Anderson's disease (chylomicron retention disease): a new mutation in the SARA2 gene associated with muscular and cardiac abnormalities. Clin. Genet. 2008, 74:546-552.
112. Papisov M., Weissleder R. Drug delivery to lymphatic tissue. Crit. Rev. Ther. Drug Carrier Syst. 1996, 13:57-84.
113. Weiss L. The pathophysiology of metastasis within the lymphatic system. Lymphatic System Metastases 1988, 2. Hall, Boston. L. Weiss, H. Gilbert, S. Ballon (Eds.).
114. Ohtake E., Matsui K. Lymphoscintigraphy in patients with lymphedema. A new approach using intradermal injections of technetium-99m human serum albumin. Clin. Nucl. Med. 1986, 11:474-478.
115. Mariani G., Erba P., Manca G., Villa G., Gipponi M., Boni G., Buffoni F., Suriano S., Castagnola F., Bartolomei M., Strauss H.W. Radioguided sentinel lymph node biopsy in patients with malignant cutaneous melanoma: the nuclear medicine contribution. J. Surg. Oncol. 2004, 85:141-151.
116. Hussain N., Jaitley V., Florence A.T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 2001, 50:107-142.
117. Tanigawa N., Satomura K., Hikasa Y., Hashida M., Muranishi S., Sezaki H. Surgical chemotherapy against lymph node metastases: an experimental study. Surgery 1980, 87:147-152.
118. Gipponi M., Bassetti C., Canavese G., Catturich A., Di Somma C., Vecchio C., Nicolo G., Schenone F., Tomei D., Cafiero F. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J. Surg. Oncol. 2004, 85:102-111.
119. Witte C.L., Witte M.H. Disorders of lymph flow. Acad. Radiol. 1995, 2:324-334.
120. Witte M.H., Jones K., Wilting J., Dictor M., Selg M., McHale N., Gershenwald J.E., Jackson D.G. Structure function relationships in the lymphatic system and implications for cancer biology. Cancer Metastasis Rev. 2006, 25:159-184.
121. Edwards G.A., Porter C.J., Caliph S.M., Khoo S.M., Charman W.N. Animal models for the study of intestinal lymphatic drug transport. Adv. Drug Deliv. Rev. 2001, 50:45-60.
122. Khoo S.M., Shackleford D.M., Porter C.J., Edwards G.A., Charman W.N. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm. Res. 2003, 20:1460-1465.
123. Lespine A., Chanoit G., Bousquet-Melou A., Lallemand E., Bassissi F.M., Alvinerie M., Toutain P.L. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs. Eur. J. Pharm. Sci. 2006, 27:37-43.
124. White D.G., Story M.J., Barnwell S.G. An experimental animal model for studying the effects of a novel lymphatic drug delivery system for propranolol. Int. J. Pharm. 1991, 69:169-174.
125. Onizuka M., Flatebo T., Nicolaysen G. Lymph flow pattern in the intact thoracic duct in sheep. J. Physiol. 1997, 503(Pt 1):223-234.
126. Segrave A.M., Mager D.E., Charman S.A., Edwards G.A., Porter C.J. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J. Pharmacol. Exp. Ther. 2004, 309:1085-1092.
127. Kagan L., Gershkovich P., Mendelman A., Amsili S., Ezov N., Hoffman A. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur. J. Pharm. Biopharm. 2007, 67:759-765.
128. Dahan A., Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur. J. Pharm. Sci. 2005, 24:381-388.
129. Pidlich J., Renner F., Ellinger A., Huttinger M., Pavelka M., Gangl A. Effect of pluronic L-81 on intestinal lipoprotein secretion in the rat. Dig. Dis. Sci. 1996, 41:1445-1451.
130. Charman W.N., Stella V.J. Estimating the maximal potentital for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 1986, 33:175-178.
131. Porter C.J.H., Charman W.N. Model systems for intestinal lymphatic transport studies. Models for Assessing Drug Absorption and Metabolism 1996, 85-102. Plenum Press, New York. R.T. Borchardt, P.L. Smith, G. Wilson (Eds.).
132. Porter C.J., Charman S.A., Humberstone A.J., Charman W.N. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J. Pharm. Sci. 1996, 85:357-361.
133. Porter C.J., Charman S.A., Charman W.N. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J. Pharm. Sci. 1996, 85:351-356.
134. Jandacek R.J., Rider T., Yang Q., Woollett L.A., Tso P. Lymphatic and portal vein absorption of organochlorine compounds in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G226-G234.
135. Noguchi T., Charman W.N., Stella V.J. Lymphatic appearance of DDT in thoracic mesenteric lymph duct cannulated rats. Int. J. Pharm. 1985, 24:185-192.
136. Turner S.G., Barrowman J.A. Intestinal lymph flow and lymphatic transport of protein during fat absorption. Q. J. Exp. Physiol. Cogn. Med. Sci. 1977, 62:175-180.
137. Raub T.J., Douglas S.L., Melchior G.W., Charman W.N. Methodology for assessing intestinal lymphatic transport. Lymphatic Transport of Drugs 1992, 63-111. CRC Press, Boca Raton, FL. W.N. Charman, V.J. Stella (Eds.).
138. Hauss D., Fogal S., Ficorilli J. Chronic collection of mesenteric lymph from conscious, tethered rats. Contemp. Top. Lab. Anim. Sci. 1998, 37:56-58.
139. Khoo S.M., Porter C.J.H., Edwards G.A., Charman W.N. A novel triple-canulaed conscious dog model for assessment of the absorption, enterocyte-based metablism and lymphocyte transport of candidate lipophilic drugs. Pharm. Sci. 1999, 1:S647.
140. Rajpal S.G., Kirkpatrick J.R. Creation of a thoracic duct fistula: an improved technique. J. Surg. Res. 1972, 13:260-261.
141. Kararli T.T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 1995, 16:351-380.
142. Jensen L.T., Olesen H.P., Risteli J., Lorenzen I. External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolites in lymph. Lab. Anim. Sci. 1990, 40:620-624.
143. Chen S.A., Sawchuk R.J., Brundage R.C., Horvath C., Mendenhall H.V., Gunther R.A., Braeckman R.A. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. J. Pharmacol. Exp. Ther. 2000, 293:248-259.
144. Charman S.A., Segrave A.M., Edwards G.A., Porter C.J. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J. Pharm. Sci. 2000, 89:168-177.
145. Porter C.J., Edwards G.A., Charman S.A. Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv. Drug Deliv. Rev. 2001, 50:157-171.
146. Girardet R.E., Benninghoff D.L. Surgical techniques for long-term study of thoracic duct lymph circulation in dogs. J. Surg. Res. 1973, 15:168-175.
147. Fish J.C., Sarles H.E., Mattingly A.T., Ross M.V., Remmers A.R. Preparation of chronic thoracic duct lymph fistulas in man and laboratory animals. J. Surg. Res. 1969, 9:101-106.
148. Gralla E.J., Cappiello F.M., Jonas A.M. Technique for chronic cannulation of the canine thoracic duct. Am. J. Vet. Res. 1973, 34:285-287.
149. Dedo D.D., Ogura J.H. Exteriorization of thoracic duct lymph. Theoretical considerations and an experimental model. Arch. Otolaryngol. 1975, 101:671-674.
150. Witte C.L., Witte M.H., Cole W.R. A simplified method for cannulation of the normal canine cervical thoracic duct. Lymphology 1970, 3:159-161.
151. Briscoe D.E. Canine thoracic duct cannulation revisited. Lymphology 1981, 14:32-34.
152. Caliph S.M., Charman W.N., Porter C.J. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci. 2000, 89:1073-1084.
153. Murthy S., Albright E., Mathur S.N., Field F.J. Effect of eicosapentaenoic acid on triacylglycerol transport in CaCo-2 cells. Biochim. Biophys. Acta 1990, 1045:147-155.
154. Kam N.T., Albright E., Mathur S.N., Field F.J. Inhibition of acylcoenzyme A: cholesterol acyltransferase activity in CaCo-2 cells results in intracellular triglyceride accumulation. J. Lipid Res. 1989, 30:371-377.
155. Kam N.T., Albright E., Mathur S., Field F.J. Effect of lovastatin on acyl-CoA: cholesterol O-acyltransferase (ACAT) activity and the basolateral-membrane secretion of newly synthesized lipids by CaCo-2 cells. Biochem. J. 1990, 272:427-433.
156. Traber M.G., Kayden H.J., Rindler M.J. Polarized secretion of newly synthesized lipoproteins by the Caco-2 human intestinal cell line. J. Lipid Res. 1987, 28:1350-1363.
157. Seeballuck F., Ashford M.B., O'Driscoll C.M. The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm. Res. 2003, 20:1085-1092.
158. Seeballuck F., Lawless E., Ashford M.B., O'Driscoll C.M. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm. Res. 2004, 21:2320-2326.
159. Karpf D.M., Holm R., Garafalo C., Levy E., Jacobsen J., Mullertz A. Effect of different surfactants in biorelevant medium on the secretion of a lipophilic compound in lipoproteins using Caco-2 cell culture. J. Pharm. Sci. 2006, 95:45-55.
160. O'Driscoll C.M., Griffin B.T. Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations. Adv. Drug Deliv. Rev. 2008, 60:617-624.
161. Murthy S., Albright E., Mathur S.N., Davidson N.O., Field F.J. Apolipoprotein B mRNA abundance is decreased by eicosapentaenoic acid in CaCo-2 cells. Effect on the synthesis and secretion of apolipoprotein B. Arterioscler. Thromb. 1992, 12:691-700.
162. Hussain M.M., Kancha R.K., Zhou Z., Luchoomun J., Zu H., Bakillah A. Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Biochim. Biophys. Acta 1996, 1300:151-170.
163. Trotter P.J., Storch J. Fatty acid esterification during differentiation of the human intestinal cell line Caco-2. J. Biol. Chem. 1993, 268:10017-10023.
164. Gershkovich P., Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur. J. Pharm. Sci. 2005, 26:394-404.
165. Crison J.R., Shah V.P., Skelly J.P., Amidon G.L. Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. J. Pharm. Sci. 1996, 85:1005-1011.
166. Crison J.R., Weiner N.D., Amidon G.L. Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. J. Pharm. Sci. 1997, 86:384-388.
167. Dressman J.B., Vertzoni M., Goumas K., Reppas C. Estimating drug solubility in the gastrointestinal tract. Adv. Drug Deliv. Rev. 2007, 59:591-602.
168. Vogt M., Kunath K., Dressman J.B. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur. J. Pharm. Biopharm. 2008, 68:330-337.
169. Dahan A., Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J. Control Release 2008, 129:1-10.
170. Alvarez F.J., Stella V.J. The role of calcium ions and bile salts on the pancreatic lipase-catalyzed hydrolysis of triglyceride emulsions stabilized with lecithin. Pharm. Res. 1989, 6:449-457.
171. Porter C.J., Charman W.N. In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev. 2001, 50(Suppl. 1):S127-S147.
172. Armand M., Borel P., Pasquier B., Dubois C., Senft M., Andre M., Peyrot J., Salducci J., Lairon D. Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. Am. J. Physiol. 1996, 271:G172-G183.
173. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15:698-705.
174. Zangenberg N.H., Mullertz A., Kristensen H.G., Hovgaard L. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur. J. Pharm. Sci. 2001, 14:237-244.
175. Porter C.J., Trevaskis N.L., Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 2007, 6:231-248.
176. Holm R., Hoest J. Successful in silico predicting of intestinal lymphatic transfer. Int. J. Pharm. 2004, 272:189-193.
177. Ichihashi T., Nagasaki T., Takagishi Y., Yamada H. A quantitative concept of the mechanism of intestinal lymphatic transfer of lipophilic molecules. Pharm. Res. 1994, 11:508-512.
178. Myers R.A., Stella V.J. Factors affecting the lymphaic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int. J. Pharm. 1992, 80:511-562.
179. Hauss D.J., Mehta S.C., Radebaugh G.W. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int. J. Pharm. 1994, 108:85-93.
180. Palm K., Luthman K., Ungell A.L., Strandlund G., Artursson P. Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. 1996, 85:32-39.
181. Krarup L.H., Christensen I.T., Hovgaard L., Frokjaer S. Predicting drug absorption from molecular surface properties based on molecular dynamics simulations. Pharm. Res. 1998, 15:972-978.
182. Norinder U., Osterberg T., Artursson P. Theoretical calculation and prediction of intestinal absorption of drugs in humans using MolSurf parametrization and PLS statistics. Eur. J. Pharm. Sci. 1999, 8:49-56.
183. Cruciani G., Crivori P., Carrupt P.A., Testa B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. Thoechem 2000, 503:17-30.
184. Cruciani G., Pastor M., Guba W. VolSurf: a new tool for the pharmacokinetics optimization of lead compounds. Eur. J. Pharm. Sci. 2000, 11:S29-S39.
185. Meylan W.M., Howard P.H. Atom/fragment contribution method for estimating octanol-water partition coefficients. J. Pharm. Sci. 1995, 84:83-92.
186. Wold S., Johansson E., Cocchi M. PLS-partial least-squares projections to latent structures. 3D QSAR in Drug Design 1993, 523-550. Escom, Leiden. H. Kubinyi (Ed.).
187. McConnell E.L., Fadda H.M., Basit A.W. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm. 2008, 364:213-226.
188. Yu L.X., Lipka E., Crison J.R., Amidon G.L. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev. 1996, 19:359-376.
189. Sue Masters B., Marohnic C.C. Cytochromes P450 - a family of proteins and scientists-understanding their relationships. Drug Metab. Rev. 2006, 38:209-225.
190. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
191. Ritter J.K. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 2000, 129:171-193.
192. Tukey R.H., Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40:581-616.
193. Murad F., Haynes R.C. Androgens and anabolic steroids. The Pharmacological Basis of Therapeutics 1980, 1448. MacMillan, New York. A.G. Gilman, L.S. Goodman, A. Gilman (Eds.).
194. Daggett P.R., Wheeler M.J., Nabarro J.D. Oral testosterone, a reappraisal. Horm. Res. 1978, 9:121-129.
195. Coert A., Geelen J., de Visser J., van der Vies J. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol. (Copenh) 1975, 79:789-800.
196. Van Veld P.A., Vetter R.D., Lee R.F., Patton J.S. Dietary fat inhibits the intestinal metabolism of the carcinogen benzo[a]pyrene in fish. J. Lipid Res. 1987, 28:810-817.
197. Vetter R.D., Carey M.C., Patton J.S. Coassimilation of dietary fat and benzo(a)pyrene in the small intestine: an absorption model using the killifish. J. Lipid Res. 1985, 26:428-434.
198. Reubsaet F.A., Veerkamp J.H., Bukkens S.G., Trijbels J.M., Monnens L.A. Acyl-CoA oxidase activity and peroxisomal fatty acid oxidation in rat tissues. Biochim. Biophys. Acta 1988, 958:434-442.
199. Haunerland N.H. Fatty acid binding protein in locust and mammalian muscle. Comparison of structure, function and regulation. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 1994, 109:199-208.
200. Veerkamp J.H., van Moerkerk H.T. Fatty acid-binding protein and its relation to fatty acid oxidation. Mol. Cell. Biochem. 1993, 123:101-106.
201. Stremmel W., Pohl L., Ring A., Herrmann T. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 2001, 36:981-989.
202. Agellon L.B., Toth M.J., Thomson A.B. Intracellular lipid binding proteins of the small intestine. Mol. Cell. Biochem. 2002, 239:79-82.
203. Chow S.L., Hollander D. A dual, concentration-dependent absorption mechanism of linoleic acid by rat jejunum in vitro. J. Lipid Res. 1979, 20:349-356.
204. David H.R., Zhu L.J., Hoos L.M., Tetzloff G., Maguire M., Liu J., Yao X., Iyier S.P., Lam M.H., Lund E.G., Detmers P.A., Graziano M.P., Altmann S.W. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 2004, 279:33586-33592.
205. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., Iyier S.P., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., Graziano M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
206. Sarkadi B., Homolya L., Szakacs G., Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 2006, 86:1179-1236.
207. Wakabayashi K., Tamura A., Saito H., Onishi Y., Ishikawa T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab. Rev. 2006, 38:371-391.
208. Borst P., Zelcer N., van Helvoort A. ABC transporters in lipid transport. Biochim. Biophys. Acta 2000, 1486:128-144.
209. Schmitz G., Langmann T., Heimerl S. Role of ABCG1 and other ABCG famly members in lipid metabolism. J. Lipid Res. 2001, 42:1513-1520.
210. Levy E., Spahis S., Sinnett D., Peretti N., Maupas-Schwalm F., Delvin E., Lambert M., Lavoie M.A. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol. 2007, 18:310-318.
211. Repa J.J., Turley S.D., Lobaccaro J.A., Medina J., Li L., Lustig K., Shan B., Heyman R.A., Dietschy J.M., Mangelsdorf D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524-1529.
212. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schultz J., Kwiterovich P., Shan B., Barnes R., Hobbs H.H. Accumulation of dietary cholesterol in sitosterolemia cuased by mutations in adjacent ABC transporters. Science 2000, 290:1771-1775.
213. Evans A.M. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther. Drug Monit. 2000, 22:131-136.
214. Hunter J., Hirst B.H., Simmons N.L. Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. Br. J. Cancer 1991, 64:437-444.
215. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4028-4033.
216. Stride B.D., Grant C.E., Loe D.W., Hipfner D.R., Cole S.P., Deeley R.G. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol. Pharmacol. 1997, 52:344-353.
217. de Jong M.C., Slootstra J.W., Scheffer G.L., Schroeijers A.B., Puijk W.C., Dinkelberg R., Kool M., Broxterman H.J., Meloen R.H., Scheper R.J. Peptide transport by the multidrug resistance protein MRP1. Cancer Res. 2001, 61:2552-2557.
218. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54:5902-5910.
219. Kawabe T., Chen Z.S., Wada M., Uchiumi T., Ono M., Akiyama S., Kuwano M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 1999, 456:327-331.
220. Deguchi T., Kusuhara H., Takadate A., Endou H., Otagiri M., Sugiyama Y. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 2004, 65:162-174.
221. Shugarts S., Benet L.Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 2009, 26:2039-2054.
222. Benet L.Z., Cummins C.L., Wu C.Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 2004, 277:3-9.
223. Cummins C.L., Jacobsen W., Benet L.Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 2002, 300:1036-1045.
224. Charman W.N., Porter C.J., Mithani S., Dressman J.B. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 1997, 86:269-282.
225. Aungst B.J. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci. 1993, 82:979-987.
226. Porter C.J., Kaukonen A.M., Boyd B.J., Edwards G.A., Charman W.N. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res. 2004, 21:1405-1412.
227. Dahan A., Duvdevani R., Dvir E., Elmann A., Hoffman A. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J. Control Release 2007, 119:86-93.
228. Dahan A., Duvdevani R., Shapiro I., Elmann A., Finkelstein E., Hoffman A. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J. Control Release 2008, 126:1-9.
229. Kossena G.A., Charman W.N., Wilson C.G., O'Mahony B., Lindsay B., Hempenstall J.M., Davison C.L., Crowley P.J., Porter C.J. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm. Res. 2007, 24:2084-2096.
230. Caliph S.M., Faassen W.A., Vogel G.M., Porter C.J. Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues. Curr. Drug Deliv. 2009, 6:359-366.
231. Humberstone A.J., Charman W.N. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 1997, 25:103-128.
232. Charman W.N., Porter C.J.H. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv. Drug Deliv. Rev. 1996, 19:149-169.
233. O'Driscoll C.M. Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 2002, 15:405-415.
234. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 2000, 11(Suppl. 2):S93-S98.
235. Pouton C.W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 2006, 29:278-287.
236. Pouton C.W., Porter C.J. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv. Drug Deliv. Rev. 2008, 60:625-637.
237. Porter C.J., Pouton C.W., Cuine J.F., Charman W.N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 2008, 60:673-691.
238. Holm R., Porter C.J., Edwards G.A., Mullertz A., Kristensen H.G., Charman W.N. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur. J. Pharm. Sci. 2003, 20:91-97.
239. Constantinides P.P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 1995, 12:1561-1572.
240. Porter C.J., Charman W.N. Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J. Recept. Signal Transduct. Res. 2001, 21:215-257.
241. Porter C.J.H., Charman W.N. Uptake of drugs into the intestinal lymphatics after oral administration. Adv. Drug Deliv. Rev. 1997, 71-89.
242. Noguchi T., Charman W.N., Stella V.J. The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters. Int. J. Pharm. 1985, 24:173-184.
243. Ichihashi T., Kinoshita H., Takagishi Y., Yamada H. Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats. J. Pharm. Pharmacol. 1992, 44:560-564.
244. Cheema M., Palin K.J., Davis S.S. Lipid vehicles for intestinal lymphatic drug absorption. J. Pharm. Pharmacol. 1987, 39:55-56.
245. MacGregor K.J., Embleton J.K., Lacy J.E., Perry E.A., Solomon L.J., Seager H., Pouton C.W. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv. Drug Deliv. Rev. 1997, 33-46.
246. Cuine J.F., McEvoy C.L., Charman W.N., Pouton C.W., Edwards G.A., Benameur H., Porter C.J. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J. Pharm. Sci. 2008, 97:995-1012.
247. Charman W.N., Stella V.J. Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int. J. Pharm. 1986, 33:165-172.
248. Stella V.J., Pochopin N.L. Lipophilic prodrugs and the promotion of the intestinal lymphatic drug transport. Lymphatic Transport of Drugs 1992, 181-210. CRC Press, Boca Raton, FL. W.N. Charman, V.J. Stella (Eds.).
249. Lambert D.M. Rationale and applications of lipids as prodrug carriers. Eur. J. Pharm. Sci. 2000, 11(Suppl. 2):S15-S27.
250. Khan M.S., Akhter M. Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen. Eur. J. Med. Chem. 2005, 40:371-376.
251. Khan M.S., Akhter M. Glyceride derivatives as potential prodrugs: synthesis, biological activity and kinetic studies of glyceride derivatives of mefenamic acid. Pharmazie 2005, 60:110-114.
252. Khan M.S., Akhter M. Synthesis, biological evaluation and kinetic studies of glyceride prodrugs of diclofenac. Indian J. Exp. Biol. 2004, 42:1066-1072.
253. Lambert D.M., Scriba G.K.E., Gallez B., Poupaert J.H., Dumont P. Glyceride conjugates as drug carriers. Curr. Med. Chem. 1995, 1:376-391.
254. Sakai A., Mori N., Shuto S., Suzuki T. Deacylation-reacylation cycle: a possible absorption mechanism for the novel lymphotropic antitumor agent dipalmitoylphosphatidylfluorouridine in rats. J. Pharm. Sci. 1993, 82:575-578.
255. Sugihara J., Furuuchi S., Nakano K., Harigaya S. Studies on intestinal lymphatic absorption of drugs. I. Lymphatic absorption of alkyl ester derivatives and alpha-monoglyceride derivatives of drugs. J. Pharmacobiodyn. 1988, 11:369-376.
256. Sugihara J., Furuuchi S., Ando H., Takashima K., Harigaya S. Studies on intestinal lymphatic absorption of drugs. II. Glyceride prodrugs for improving lymphatic absorption of naproxen and nicotinic acid. J. Pharmacobiodyn. 1988, 11:555-562.
257. Kennedy B.P., Payette P., Mudgett J., Vadas P., Pruzanski W., Kwan M., Tang C., Rancourt D.E., Cromlish W.A. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 1995, 270:22378-22385.
258. Shackleford D.M., Porter C.J.H., Charman W.N. Lymphatic absorption of orally administered drugs. Prodrugs: Challenges and Rewards 2007, 653-682. AAPS Press, New York. V.J. Stella, R.T. Borchardt, M.J. Hageman, R. Oliyai, H. Maag, J. Tilley (Eds.).
259. Martin-Facklam M., Burhenne J., Ding R., Fricker R., Mikus G., Walter-Sack I., Haefeli W.E. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br. J. Clin. Pharmacol. 2002, 53:576-581.
260. Bravo Gonzalez R.C., Huwyler J., Boess F., Walter I., Bittner B. In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam. Biopharm. Drug Dispos. 2004, 25:37-49.
261. Rege B.D., Kao J.P., Polli J.E. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 2002, 16:237-246.
262. Mountfield R.J., Senepin S., Schleimer M., Walter I., Bittner B. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int. J. Pharm. 2000, 211:89-92.
263. Johnson B.M., Charman W.N., Porter C.J. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002, 4:E40.
264. Sachs-Barrable K., Thamboo A., Lee S.D., Wasan K.M. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 2007, 10:319-331.
265. Zordan-Nudo T., Ling V., Liu Z., Georges E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res. 1993, 53:5994-6000.
266. Batrakova E., Lee S., Li S., Venne A., Alakhov V., Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 1999, 16:1373-1379.
267. Dean M., Hamon Y., Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 2001, 42:1007-1017.
268. Jia J.X., Wasan K.M. Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-d-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 2008, 11:45-62.
269. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 1999, 16:1550-1556.
270. Chervinsky D.S., Brecher M.L., Hoelcle M.J. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer. Res. 1993, 13:93-96.
271. Trevaskis N.L., Shackleford D.M., Charman W.N., Edwards G.A., Gardin A., Appel-Dingemanse S., Kretz O., Galli B., Porter C.J. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm. Res. 2009, 26:1486-1495.
272. Gershkovich P., Qadri B., Yacovan A., Amselem S., Hoffman A. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur. J. Pharm. Sci. 2007, 31:298-305.
273. Ichihashi T., Kinoshita H., Takagishi Y., Yamada H. Effect of bile on absorption of mepitiostane by the lymphatic system in rats. J. Pharm. Pharmacol. 1992, 44:565-569.
274. Grimus R.C., Schuster I. The role of the lymphatic transport in the enteral absorption of naftifine by the rat. Xenobiotica; the fate of foreign compounds in biological systems 1984, 14:287-294.
275. Palin K.J., Wilson C.G. The effect of different oils on the absorption of probucol in the rat. J. Pharm. Pharmacol. 1984, 36:641-643.
276. Ueda C.T., Lemaire M., Gsell G., Nussbaumer K. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats. Biopharm. Drug Dispos. 1983, 4:113-124.
277. Hauss D.J., Fogal S.E., Ficorilli J.V., Price C.A., Roy T., Jayaraj A.A., Keirns J.J. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 1998, 87:164-169.
278. Nankervis R., Davis S.S., Day N.H., Shaw P.N. Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle. Int. J. Pharm. 1996, 130:57-64.
279. Sieber S.M., Cohn V.H., Wynn W.T. The entry of foreign compounds into the thoracic duct lymph of the rat. Xenobiotica; the fate of foreign compounds in biological systems 1974, 4:265-284.
280. Laher J.M., Rigler M.W., Vetter R.D., Barrowman J.A., Patton J.S. Similar bioavailability and lymphatic transport of benzo(a)pyrene when administered to rats in different amounts of dietary fat. J. Lipid Res. 1984, 25:1337-1342.
281. O'Driscoll C.M., Myers R.A., Stella V.J. Blood and lymph transport of DDT after oral and parenteral administration to anaesthetised rats. Int. J. Pharm. 1991, 73:177-183.
282. Khoo S.M., Porter C.J.H., Edwards G.A., Charman W.N. Intestinal lymphatic transport is the primary route for halofantrine after oral postprandial administration. Pharm. Sci. 1999, 1:S-624.
283. Takada K., Yoshimura H., Shibata N., Masuda Y., Yoshikawa H., Muranishi S., Yasumura T., Oka T. Effect of administration route on the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles. J. Pharmacobiodyn. 1986, 9:156-160.
284. Ichihashi T., Kinoshita H., Takagishi Y., Yamada H. Intrinsic lymphatic partition rate of mepitiostane, epitiostanol, and oleic acid absorbed from rat intestine. Pharm. Res. 1991, 8:1302-1306.
285. Neilson P.B., Mullertz A., Norling T., Kristensen H.G. Comparison of the lymphatic transport of a lipophilic drug from vehicles containing a-tocopherol and/or triglycerides in rats. J. Pharm. Pharmacol. 2001, 53:1439-1445.
286. Kwei G.Y., Novak L.B., Hettrick L.H., Reiss E.R., Fong E.K., Olah T.V., Loper A.E. Lymphatic uptake of MK-386, a sterol 5a-reductase inhibitor, from aqueous and lipid formulations. Int. J. Pharm. 1998, 164:37-44.
287. Liu H.X., Adachi I., Horikoshi I., Ueno M. Mechanism of promotion of lymphatic drug absorption by milk fat globule membrane. Int. J. Pharm. 1995, 118:55-64.